메뉴 건너뛰기




Volumn 14, Issue 1, 2012, Pages 26-32

Role of c-reactive protein when prescribing a Statin

Author keywords

C reactive protein; CRP; High risk strategy; LDL cholesterol; Prediction; Screening; Variability

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; ROSUVASTATIN;

EID: 84857631299     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0218-8     Document Type: Article
Times cited : (3)

References (40)
  • 1
    • 0037126526 scopus 로고    scopus 로고
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
    • (2002) Circulation , vol.106 , Issue.25 , pp. 3143-421
  • 4
    • 0021983786 scopus 로고
    • Sick individuals and sick populations
    • G Rose 1985 Sick individuals and sick populations Int J Epidemiol. 14 1 32 38 3872850 10.1093/ije/14.1.32 1:STN:280:DyaL2M7otFynsA%3D%3D (Pubitemid 15109489)
    • (1985) International Journal of Epidemiology , vol.14 , Issue.1 , pp. 32-38
    • Rose, G.1
  • 5
    • 67651121913 scopus 로고    scopus 로고
    • Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000
    • 19541856 10.1093/aje/kwp150
    • S Capewell DK Hayes ES Ford JA Critchley JB Croft KJ Greenlund, et al. 2009 Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000 Am J Epidemiol. 170 2 229 236 19541856 10.1093/aje/kwp150
    • (2009) Am J Epidemiol. , vol.170 , Issue.2 , pp. 229-236
    • Capewell, S.1    Hayes, D.K.2    Ford, E.S.3    Critchley, J.A.4    Croft, J.B.5    Greenlund, K.J.6
  • 6
    • 0034716468 scopus 로고    scopus 로고
    • Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations
    • K Kuulasmaa H Tunstall-Pedoe A Dobson S Fortmann S Sans H Tolonen, et al. 2000 Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations Lancet. 355 9205 675 687 10703799 10.1016/S0140-6736(99)11180-2 1:STN:280:DC%2BD3c7ms1Gguw%3D%3D (Pubitemid 30107623)
    • (2000) Lancet , vol.355 , Issue.9205 , pp. 675-687
    • Kuulasmaa, K.1    Tunstall-Pedoe, H.2    Dobson, A.3    Fortmann, S.4    Sans, S.5    Tolonen, H.6    Evans, A.7    Ferrario, M.8    Tuomilehto, J.9
  • 7
    • 0033545342 scopus 로고    scopus 로고
    • Acute-phase proteins and other systemic responses to inflammation
    • DOI 10.1056/NEJM199902113400607
    • C Gabay I Kushner 1999 Acute-phase proteins and other systemic responses to inflammation N Engl J Med. 340 6 448 454 9971870 10.1056/NEJM199902113400607 1:STN:280:DyaK1M7it1KhtA%3D%3D (Pubitemid 29084777)
    • (1999) New England Journal of Medicine , vol.340 , Issue.6 , pp. 448-454
    • Gabay, C.1    Kushner, I.2
  • 8
    • 0025177196 scopus 로고
    • Elevation of C-reactive protein in 'active' coronary artery disease
    • DOI 10.1016/0002-9149(90)90079-G
    • BC Berk WS Weintraub RW Alexander 1990 Elevation of C-reactive protein in "active" coronary artery disease Am J Cardiol. 65 3 168 172 2296885 10.1016/0002-9149(90)90079-G 1:STN:280:DyaK3c7hvFCmsg%3D%3D (Pubitemid 20031251)
    • (1990) American Journal of Cardiology , vol.65 , Issue.3 , pp. 168-172
    • Berk, B.C.1    Weintraub, W.S.2    Alexander, R.W.3
  • 9
    • 0141841612 scopus 로고    scopus 로고
    • High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
    • DOI 10.1161/01.CIR.0000091404.09558.AF
    • S Kinlay GG Schwartz AG Olsson N Rifai SJ Leslie WJ Sasiela, et al. 2003 High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation. 108 13 1560 1566 12975259 10.1161/01.CIR.0000091404.09558.AF 1:CAS:528:DC%2BD3sXnsVKrs7c%3D (Pubitemid 37187781)
    • (2003) Circulation , vol.108 , Issue.13 , pp. 1560-1566
    • Kinlay, S.1    Schwartz, G.G.2    Olsson, A.G.3    Rifai, N.4    Leslie, S.J.5    Sasiela, W.J.6    Szarek, M.7    Libby, P.8    Ganz, P.9
  • 10
    • 0027933081 scopus 로고
    • The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
    • DOI 10.1056/NEJM199408183310701
    • G Liuzzo LM Biasucci JR Gallimore RL Grillo AG Rebuzzi MB Pepys, et al. 1994 The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N Engl J Med. 331 7 417 424 7880233 10.1056/ NEJM199408183310701 1:STN:280:DyaK2czgvFKruw%3D%3D (Pubitemid 24247397)
    • (1994) New England Journal of Medicine , vol.331 , Issue.7 , pp. 417-424
    • Liuzzo, G.1    Biasucci, L.M.2    Gallimore, J.R.3    Grillo, R.L.4    Rebuzzi, A.G.5    Pepys, M.B.6    Maseri, A.7
  • 11
    • 73449130797 scopus 로고    scopus 로고
    • C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis
    • 20031199 10.1016/S0140-6736(09)61717-7 This is a large meta-analysis of conventional risk factors and CRP on cardiovascular risk and shows a modest relationship between CRP and events in groups of subjects.
    • S Kaptoge E Di Angelantonio G Lowe MB Pepys SG Thompson R Collins, et al. 2010 C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet. 375 9709 132 140 20031199 10.1016/S0140-6736(09)61717-7 This is a large meta-analysis of conventional risk factors and CRP on cardiovascular risk and shows a modest relationship between CRP and events in groups of subjects.
    • (2010) Lancet. , vol.375 , Issue.9709 , pp. 132-140
    • Kaptoge, S.1    Di Angelantonio, E.2    Lowe, G.3    Pepys, M.B.4    Thompson, S.G.5    Collins, R.6
  • 13
    • 0037197780 scopus 로고    scopus 로고
    • Elevated C-reactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies
    • DOI 10.1161/01.CIR.0000015507.29953.38
    • AP Burke RP Tracy F Kolodgie GT Malcom A Zieske R Kutys, et al. 2002 Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies Circulation. 105 17 2019 2023 11980679 10.1161/01.CIR.0000015507.29953.38 1:CAS:528:DC%2BD38Xkt1Cht7o%3D (Pubitemid 34465262)
    • (2002) Circulation , vol.105 , Issue.17 , pp. 2019-2023
    • Burke, A.P.1    Tracy, R.P.2    Kolodgie, F.3    Malcom, G.T.4    Zieske, A.5    Kutys, R.6    Pestaner, J.7    Smialek, J.8    Virmani, R.9
  • 14
    • 0029800916 scopus 로고    scopus 로고
    • Stability and instability: Two faces of coronary atherosclerosis: The Paul Dudley White lecture 1995
    • MJ Davies 1996 Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995 Circulation. 94 8 2013 2020 8873680 1:STN:280:DyaK2s%2FislGnsw%3D%3D (Pubitemid 26349317)
    • (1996) Circulation , vol.94 , Issue.8 , pp. 2013-2020
    • Davies, M.J.1
  • 15
    • 0029090411 scopus 로고
    • Coronary plaque disruption
    • 7634481 1:STN:280:DyaK2MzmtFWlsw%3D%3D
    • E Falk PK Shah V Fuster 1995 Coronary plaque disruption Circulation. 92 3 657 671 7634481 1:STN:280:DyaK2MzmtFWlsw%3D%3D
    • (1995) Circulation. , vol.92 , Issue.3 , pp. 657-671
    • Falk, E.1    Shah, P.K.2    Fuster, V.3
  • 16
    • 60149088617 scopus 로고    scopus 로고
    • Critical appraisal of CRP measurement for the prediction of coronary heart disease events: New data and systematic review of 31 prospective cohorts
    • 18930961 10.1093/ije/dyn217
    • T Shah JP Casas JA Cooper I Tzoulaki R Sofat V McCormack, et al. 2009 Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts Int J Epidemiol. 38 1 217 231 18930961 10.1093/ije/dyn217
    • (2009) Int J Epidemiol. , vol.38 , Issue.1 , pp. 217-231
    • Shah, T.1    Casas, J.P.2    Cooper, J.A.3    Tzoulaki, I.4    Sofat, R.5    McCormack, V.6
  • 17
    • 28344436928 scopus 로고    scopus 로고
    • C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study
    • DOI 10.1001/archinte.165.21.2473
    • PW Wilson BH Nam M Pencina RB D'Agostino Sr EJ Benjamin CJ O'Donnell 2005 C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study Arch Intern Med. 165 21 2473 2478 16314543 10.1001/archinte.165.21.2473 1:CAS:528:DC%2BD2MXhtlamsrjI (Pubitemid 41720008)
    • (2005) Archives of Internal Medicine , vol.165 , Issue.21 , pp. 2473-2478
    • Wilson, P.W.F.1    Nam, B.-H.2    Pencina, M.3    D'Agostino Sr., R.B.4    Benjamin, E.J.5    O'Donnell, C.J.6
  • 18
    • 78650709475 scopus 로고    scopus 로고
    • 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • 21098428 10.1161/CIR.0b013e3182051b4c
    • P Greenland JS Alpert GA Beller EJ Benjamin MJ Budoff ZA Fayad, et al. 2010 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation. 122 25 e584 e636 21098428 10.1161/CIR.0b013e3182051b4c
    • (2010) Circulation. , vol.122 , Issue.25
    • Greenland, P.1    Alpert, J.S.2    Beller, G.A.3    Benjamin, E.J.4    Budoff, M.J.5    Fayad, Z.A.6
  • 19
    • 2342571696 scopus 로고    scopus 로고
    • Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker
    • DOI 10.1093/aje/kwh101
    • MS Pepe H Janes G Longton W Leisenring P Newcomb 2004 Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker Am J Epidemiol. 159 9 882 890 15105181 10.1093/aje/kwh101 (Pubitemid 38657490)
    • (2004) American Journal of Epidemiology , vol.159 , Issue.9 , pp. 882-890
    • Pepe, M.S.1    Janes, H.2    Longton, G.3    Leisenring, W.4    Newcomb, P.5
  • 20
    • 33644835267 scopus 로고    scopus 로고
    • The efficacy of combining several risk factors as a screening test
    • DOI 10.1258/096914105775220642
    • NJ Wald JK Morris S Rish 2005 The efficacy of combining several risk factors as a screening test J Med Screen. 12 4 197 201 16417697 10.1258/096914105775220642 (Pubitemid 43843295)
    • (2005) Journal of Medical Screening , vol.12 , Issue.4 , pp. 197-201
    • Wald, N.J.1    Morris, J.K.2    Rish, S.3
  • 21
    • 79951587253 scopus 로고    scopus 로고
    • Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction
    • 21300963 10.1161/CIRCULATIONAHA.109.912568 This review discusses the methods to assess the value of novel biomarkers and imaging studies on cardiovascular risk stratification. It concludes that most new markers (including CRP) offer minor improvements in risk stratification and that the value of novel markers of risk is as yet unproven.
    • TJ Wang 2011 Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction Circulation 123 5 551 565 21300963 10.1161/CIRCULATIONAHA.109.912568 This review discusses the methods to assess the value of novel biomarkers and imaging studies on cardiovascular risk stratification. It concludes that most new markers (including CRP) offer minor improvements in risk stratification and that the value of novel markers of risk is as yet unproven.
    • (2011) Circulation , vol.123 , Issue.5 , pp. 551-565
    • Wang, T.J.1
  • 22
    • 59749092544 scopus 로고    scopus 로고
    • C-reactive protein and coronary heart disease: Predictive test or therapeutic target?
    • 19114670 10.1373/clinchem.2008.115923 1:CAS:528:DC%2BD1MXhvVWks78%3D
    • AD Hingorani T Shah JP Casas SE Humphries PJ Talmud 2009 C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem. 55 2 239 255 19114670 10.1373/clinchem.2008.115923 1:CAS:528: DC%2BD1MXhvVWks78%3D
    • (2009) Clin Chem. , vol.55 , Issue.2 , pp. 239-255
    • Hingorani, A.D.1    Shah, T.2    Casas, J.P.3    Humphries, S.E.4    Talmud, P.J.5
  • 23
    • 0025290850 scopus 로고
    • Effectiveness and hazards of case finding for a high cholesterol concentration
    • S Kinlay RF Heller 1990 Effectiveness and hazards of case finding for a high cholesterol concentration BMJ. 300 6739 1545 1547 2372619 10.1136/bmj.300.6739.1545 1:STN:280:DyaK3czit1SntA%3D%3D (Pubitemid 20207142)
    • (1990) British Medical Journal , vol.300 , Issue.6739 , pp. 1545-1547
    • Kinlay, S.1    Heller, R.F.2
  • 24
    • 79953035510 scopus 로고    scopus 로고
    • Evaluating the clinical utility of a biomarker: A review of methods for estimating health impact
    • 21403122 10.1161/CIRCULATIONAHA.110.943860 This article discusses decision analysis models and their use in addressing the value of screening with novel risk markers.
    • MJ Pletcher M Pignone 2011 Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact Circulation 123 10 1116 1124 21403122 10.1161/CIRCULATIONAHA.110.943860 This article discusses decision analysis models and their use in addressing the value of screening with novel risk markers.
    • (2011) Circulation , vol.123 , Issue.10 , pp. 1116-1124
    • Pletcher, M.J.1    Pignone, M.2
  • 25
    • 33751181868 scopus 로고    scopus 로고
    • Inflammatory Biomarkers in Stable Atherosclerosis
    • DOI 10.1016/j.amjcard.2006.09.014, PII S0002914906017358
    • S Kinlay J Egido 2006 Inflammatory biomarkers in stable atherosclerosis Am J Cardiol. 98 11A 2P 8P 17126676 10.1016/j.amjcard.2006.09.014 1:CAS:528:DC%2BD2sXivVSjtg%3D%3D (Pubitemid 44779496)
    • (2006) American Journal of Cardiology , vol.98 , Issue.11 SUPPL.
    • Kinlay, S.1    Egido, J.2
  • 26
    • 0035963529 scopus 로고    scopus 로고
    • Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    • DOI 10.1056/NEJM200106283442601
    • PM Ridker N Rifai M Clearfield JR Downs SE Weis JS Miles, et al. 2001 Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med. 344 26 1959 1965 11430324 10.1056/NEJM200106283442601 1:CAS:528:DC%2BD3MXltFersrc%3D (Pubitemid 32568149)
    • (2001) New England Journal of Medicine , vol.344 , Issue.26 , pp. 1959-1965
    • Ridker, P.M.1    Rifai, N.2    Clearfield, M.3    Downs, J.R.4    Weis, S.E.5    Miles, J.S.6    Gotto Jr., A.M.7
  • 27
    • 77954190124 scopus 로고    scopus 로고
    • By Jove! What is a clinician to make of JUPITER?
    • 20585074 10.1001/archinternmed.2010.189 1:CAS:528:DC%2BC3cXptl2ktrw%3D
    • S Kaul RP Morrissey GA Diamond 2010 By Jove! What is a clinician to make of JUPITER? Arch Intern Med. 170 12 1073 1077 20585074 10.1001/archinternmed. 2010.189 1:CAS:528:DC%2BC3cXptl2ktrw%3D
    • (2010) Arch Intern Med. , vol.170 , Issue.12 , pp. 1073-1077
    • Kaul, S.1    Morrissey, R.P.2    Diamond, G.A.3
  • 28
    • 78049304338 scopus 로고    scopus 로고
    • The JUPITER Trial: Responding to the critics
    • 21029837 10.1016/j.amjcard.2010.08.025 One of a series of rebuttals against opinion and review articles that suggest CRP is of little clinical benefit. This article purports to show that the absolute risk benefit from rosuvastatin in JUPITER was greater in subjects with higher CRP. However, this is based on the observation of a higher absolute risk of cardiovascular events with increasing CRP coupled with similar relative risk reductions across tertiles of CRP. Calculation of the actual absolute risk reduction across tertiles of CRP show little difference in absolute risk reduction with increasing CRP in JUPITER as shown in Figure 1 of this review.
    • PM Ridker RJ Glynn 2010 The JUPITER Trial: responding to the critics Am J Cardiol. 106 9 1351 1356 21029837 10.1016/j.amjcard.2010.08.025 One of a series of rebuttals against opinion and review articles that suggest CRP is of little clinical benefit. This article purports to show that the absolute risk benefit from rosuvastatin in JUPITER was greater in subjects with higher CRP. However, this is based on the observation of a higher absolute risk of cardiovascular events with increasing CRP coupled with similar relative risk reductions across tertiles of CRP. Calculation of the actual absolute risk reduction across tertiles of CRP show little difference in absolute risk reduction with increasing CRP in JUPITER as shown in Figure 1 of this review.
    • (2010) Am J Cardiol. , vol.106 , Issue.9 , pp. 1351-1356
    • Ridker, P.M.1    Glynn, R.J.2
  • 29
    • 77955711541 scopus 로고    scopus 로고
    • Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
    • 20599004 10.1016/j.amjcard.2010.03.018 1:CAS:528:DC%2BC3cXosVWnsro%3D
    • PM Ridker J MacFadyen P Libby RJ Glynn 2010 Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Am J Cardiol. 106 2 204 209 20599004 10.1016/j.amjcard.2010.03.018 1:CAS:528:DC%2BC3cXosVWnsro%3D
    • (2010) Am J Cardiol. , vol.106 , Issue.2 , pp. 204-209
    • Ridker, P.M.1    MacFadyen, J.2    Libby, P.3    Glynn, R.J.4
  • 30
    • 79551682546 scopus 로고    scopus 로고
    • C-reactive protein concentration and the vascular benefits of statin therapy: An analysis of 20,536 patients in the Heart Protection Study
    • 10.1016/S0140-6736(10)62174-5 This analysis from the Heart Protection Study shows that although absolute risk was higher with increasing CRP over a wider range than the JUPITER study, the absolute risk reductions with statin therapy were no different. These results were converted to events per 100 person-years in Figure 1 in this review so that they could be compared to the JUPITER results. In conjunction with JUPITER, this suggests elevated CRP does not identify patients who will obtain greater benefits from high-dose statin therapy.
    • E Jonathan B Derrick L Emma P Sarah D John A Jane, et al. 2011 C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study Lancet 377 9764 469 476 10.1016/S0140-6736(10)62174-5 This analysis from the Heart Protection Study shows that although absolute risk was higher with increasing CRP over a wider range than the JUPITER study, the absolute risk reductions with statin therapy were no different. These results were converted to events per 100 person-years in Figure 1 in this review so that they could be compared to the JUPITER results. In conjunction with JUPITER, this suggests elevated CRP does not identify patients who will obtain greater benefits from high-dose statin therapy.
    • (2011) Lancet , vol.377 , Issue.9764 , pp. 469-476
    • Jonathan, E.1    Derrick, B.2    Emma, L.3    Sarah, P.4    John, D.5    Jane, A.6
  • 31
    • 72249084311 scopus 로고    scopus 로고
    • High-sensitivity C-reactive protein predicts mortality but not stroke: The Northern Manhattan Study
    • 19841382 10.1212/WNL.0b013e3181bd10bc 1:CAS:528:DC%2BD1MXht1ymtLjO
    • MS Elkind JM Luna YP Moon KM Liu SL Spitalnik MC Paik, et al. 2009 High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study Neurology. 73 16 1300 1307 19841382 10.1212/WNL.0b013e3181bd10bc 1:CAS:528:DC%2BD1MXht1ymtLjO
    • (2009) Neurology. , vol.73 , Issue.16 , pp. 1300-1307
    • Elkind, M.S.1    Luna, J.M.2    Moon, Y.P.3    Liu, K.M.4    Spitalnik, S.L.5    Paik, M.C.6
  • 32
    • 59649120505 scopus 로고    scopus 로고
    • Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: A longitudinal study
    • 19179270 10.1373/clinchem.2008.111245 1:CAS:528:DC%2BD1MXhvVWks7Y%3D This analysis demonstrates a large seasonal variation in CRP (of about 20% from winter to summer months).
    • DE Chiriboga Y Ma W Li EJ Stanek 3rd JR Hebert PA Merriam, et al. 2009 Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: a longitudinal study Clin Chem. 55 2 313 321 19179270 10.1373/clinchem.2008.111245 1:CAS:528:DC%2BD1MXhvVWks7Y%3D This analysis demonstrates a large seasonal variation in CRP (of about 20% from winter to summer months).
    • (2009) Clin Chem. , vol.55 , Issue.2 , pp. 313-321
    • Chiriboga, D.E.1    Ma, Y.2    Li, W.3    Stanek III, E.J.4    Hebert, J.R.5    Merriam, P.A.6
  • 33
    • 0035103150 scopus 로고    scopus 로고
    • Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
    • IS Ockene CE Matthews N Rifai PM Ridker G Reed E Stanek 2001 Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults Clin Chem. 47 3 444 450 11238295 1:CAS:528:DC%2BD3MXhvVOgtLw%3D (Pubitemid 32222458)
    • (2001) Clinical Chemistry , vol.47 , Issue.3 , pp. 444-450
    • Ockene, I.S.1    Matthews, C.E.2    Rifai, N.3    Ridker, P.M.4    Reed, G.5    Stanek, E.6
  • 34
    • 59649124121 scopus 로고    scopus 로고
    • Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: The role of comorbidities and environmental factors
    • 19095729 10.1373/clinchem.2008.112334
    • R Ruckerl A Peters N Khuseyinova M Andreani W Koenig C Meisinger, et al. 2009 Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors Clin Chem. 55 2 322 335 19095729 10.1373/clinchem.2008.112334
    • (2009) Clin Chem. , vol.55 , Issue.2 , pp. 322-335
    • Ruckerl, R.1    Peters, A.2    Khuseyinova, N.3    Andreani, M.4    Koenig, W.5    Meisinger, C.6
  • 35
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • 18997196 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL
    • PM Ridker E Danielson FA Fonseca J Genest AM Gotto Jr JJ Kastelein, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med. 359 21 2195 2207 18997196 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL
    • (2008) N Engl J Med. , vol.359 , Issue.21 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3    Genest, J.4    Gotto Jr., A.M.5    Kastelein, J.J.6
  • 36
    • 59649104144 scopus 로고    scopus 로고
    • Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: The JUPITER Study
    • 19095726 10.1373/clinchem.2008.120642 1:CAS:528:DC%2BD1MXhvVWks7k%3D
    • RJ Glynn JG MacFadyen PM Ridker 2009 Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study Clin Chem. 55 2 305 312 19095726 10.1373/clinchem.2008.120642 1:CAS:528:DC%2BD1MXhvVWks7k%3D
    • (2009) Clin Chem. , vol.55 , Issue.2 , pp. 305-312
    • Glynn, R.J.1    MacFadyen, J.G.2    Ridker, P.M.3
  • 37
    • 0036558577 scopus 로고    scopus 로고
    • Short-term effects of atorvastatin on C-reactive protein
    • DOI 10.1053/euhj.2001.2967
    • WF Riesen H Engler M Risch W Korte G Noseda 2002 Short-term effects of atorvastatin on C-reactive protein Eur Heart J. 23 10 794 799 12009719 10.1053/euhj.2001.2967 1:CAS:528:DC%2BD38XkvVKjtLw%3D (Pubitemid 35238493)
    • (2002) European Heart Journal , vol.23 , Issue.10 , pp. 794-799
    • Riesen, W.F.1    Engler, H.2    Risch, M.3    Korte, W.4    Noseda, G.5
  • 38
    • 0033646611 scopus 로고    scopus 로고
    • Associations between change in C-reactive protein and serum lipids during statin treatment
    • 11127936 10.3109/07853890008998838 1:CAS:528:DC%2BD3MXhtVegsLo%3D
    • TE Strandberg H Vanhanen MJ Tikkanen 2000 Associations between change in C-reactive protein and serum lipids during statin treatment Ann Med. 32 8 579 583 11127936 10.3109/07853890008998838 1:CAS:528:DC%2BD3MXhtVegsLo%3D
    • (2000) Ann Med. , vol.32 , Issue.8 , pp. 579-583
    • Strandberg, T.E.1    Vanhanen, H.2    Tikkanen, M.J.3
  • 39
    • 0036890370 scopus 로고    scopus 로고
    • Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy
    • DOI 10.1016/S0021-9150(02)00280-0, PII S0021915002002800
    • S van Wissen MD Trip TJ Smilde J de Graaf AF Stalenhoef JJ Kastelein 2002 Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy Atherosclerosis. 165 2 361 366 12417288 10.1016/S0021-9150(02)00280-0 (Pubitemid 35333363)
    • (2002) Atherosclerosis , vol.165 , Issue.2 , pp. 361-366
    • Van Wissen, S.1    Trip, M.D.2    Smilde, T.J.3    De Graaf, J.4    Stalenhoef, A.F.H.5    Kastelein, J.J.P.6
  • 40
    • 34248342266 scopus 로고    scopus 로고
    • Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein. A Meta-Analysis
    • DOI 10.1016/j.jacc.2007.01.083, PII S0735109707008364
    • S Kinlay 2007 Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis J Am Coll Cardiol. 49 20 2003 2009 17512355 10.1016/j.jacc.2007.01.083 1:CAS:528:DC%2BD2sXlsF2hur8%3D (Pubitemid 46734641)
    • (2007) Journal of the American College of Cardiology , vol.49 , Issue.20 , pp. 2003-2009
    • Kinlay, S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.